LeMaitre Vascular, Inc. (LMAT) stock analysis
Healthcare · Medical Instruments & Supplies
From the 10-K filed 2026-02-26
Business type: Franchise
How it makes money
Directly selling biologic patches and valvulotomes to surgeons drives profit, with 95% of sales generated in territories where the company employs its own representatives.
It generates profit by selling specialized instruments to over 22,000 vascular surgeons globally. Biologic offerings, including patches and grafts, represent 53% of total revenue.
Profitability is primarily driven by expanding the direct sales force to capture higher margins and implementing annual increases in average selling prices for proprietary devices like valvulotomes and carotid shunts.
What protects it: the moat
The company maintains higher prices by dominating niche, low-rivalry segments under $400 million that larger medical device competitors typically ignore.
It focuses on market segments too small to attract major diversified rivals. Management claims this lack of competition, combined with strong brand recognition and physician familiarity with its shunts and catheters, allows for pricing flexibility.
Selling direct-to-hospital in 95% of its markets further protects earnings by securing closer customer relationships and eliminating distributor turnover risk.
What growth costs
It invested $1.8 million for AndraValvulotome assets and carries $4.6 million in capitalized costs for a new enterprise resource planning system.
Growth depends heavily on acquiring complementary product lines, as internal research and development is limited. Reinvestment is also directed toward manufacturing transfers to the Massachusetts headquarters and funding clinical trials required to maintain or expand regulatory approvals, such as the XenoSure China study.
What could damage it
The company faces permanent impairment if the industry continues shifting toward endovascular procedures, as 95% of its sales rely on open surgical methods.
While vascular surgeons can perform both procedure types, the company’s product portfolio is concentrated in open vascular surgery. A more rapid adoption of minimally invasive, catheter-based treatments by hospitals and surgeons could render its core surgical instruments and biologic grafts obsolete.
About LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.